Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

Cristina Santoro, Isabella Sperduti, Roberto Latagliata, Erminia Baldacci, Barbara Anaclerico, Giuseppe Avvisati, Massimo Breccia, Francesco Buccisano, Michele Cedrone, Giuseppe Cimino, Cinzia De Gregoris, Marianna De Muro, Ambra Di Veroli, Sabrina Leonetti Crescenzi, Marco Montanaro, Enrico Montefusco, Raffaele Porrini, Angela Rago, Antonio Spadea, Francesca SpiritoNicoletta Villivà, Alesssandro Andriani, Giuliana Alimena, Maria Gabriella Mazzucconi

Research output: Contribution to journalArticle

Abstract

Aim of this study is to explore the role of different treatments on the development of secondary malignancies (SMs) in a large cohort of essential thrombocythemia (ET) patients. We report the experience of a regional cooperative group in a real-life cohort of 1026 patients with ET. We divided our population into five different groups: group 0, no treatment; group 1, hydroxyurea (HU); group 2, alkylating agents (ALK); group 3, ALK + HU sequentially or in combination; and group 4, anagrelide (ANA) and/or α-interferon (IFN) only. Patients from groups 1, 2, and 3 could also have been treated either with ANA and/or IFN in their medical history, considering these drugs not to have an additional cytotoxic potential. In all, 63 of the 1026 patients (6%) developed 64 SM during the follow-up, after a median time of 50 months (range: 2-158) from diagnosis. In univariate analysis, a statistically significant difference was found only for gender (P = 0.035) and age (P = 0.0001). In multivariate analysis, a statistically significant difference was maintained for both gender and age (gender HR1.7 [CI 95% 1.037-2.818] P = 0.035; age HR 4.190 [CI 95% 2.308-7.607] P = 0.0001). The impact of different treatments on SMs development was not statistically significant. In our series of 1026 ET patients, diagnosed and followed during a 30-year period, the different therapies administered, comprising HU and ALK, do not appear to have impacted on the development of SM. A similar rate of SMs was observed also in untreated patients. The only two variables which showed a statistical significance were male gender and age >60 years.

Original languageEnglish
Pages (from-to)1233-1239
Number of pages7
JournalCancer Medicine
Volume6
Issue number6
DOIs
Publication statusPublished - Jun 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia'. Together they form a unique fingerprint.

Cite this